Drug intelligence / Profile preview

JM3A

Development stage: Unknown
Lead developer: University of Houston

Overview

JM3A: sourced facts only. name: "We recently reported a cell surface vimentin (CSV) specific peptoid antagonist named JM3A." [PMID:38103535]; target: "We recently reported a cell surface vimentin (CSV) specific peptoid antagonist named JM3A." [PMID:38103535]; developer: "Department of Pharmacological & Pharmaceutical Sciences, University of Houston, 4349 Martin Luther King Boulevard, Health Building 2, Room 7033, Houston, TX 77204-5037, USA." [PMID:38103535]

Targets

VIM (Vimentin)

Beyond the preview

Go deeper on JM3A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JM3A.